KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Cash & Equivalents: 2009-2024

Historic Cash & Equivalents for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to $3.3 billion.

  • Teva Pharmaceutical Industries' Cash & Equivalents fell 33.62% to $2.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 billion, marking a year-over-year decrease of 33.62%. This contributed to the annual value of $3.3 billion for FY2024, which is 2.29% up from last year.
  • As of FY2024, Teva Pharmaceutical Industries' Cash & Equivalents stood at $3.3 billion, which was up 2.29% from $3.2 billion recorded in FY2023.
  • Teva Pharmaceutical Industries' 5-year Cash & Equivalents high stood at $3.3 billion for FY2024, and its period low was $2.2 billion during FY2021.
  • For the 3-year period, Teva Pharmaceutical Industries' Cash & Equivalents averaged around $3.1 billion, with its median value being $3.2 billion (2023).
  • Its Cash & Equivalents has fluctuated over the past 5 years, first decreased by 0.55% in 2021, then climbed by 29.38% in 2022.
  • Over the past 5 years, Teva Pharmaceutical Industries' Cash & Equivalents (Yearly) stood at $2.2 billion in 2020, then fell by 0.55% to $2.2 billion in 2021, then climbed by 29.38% to $2.8 billion in 2022, then grew by 15.17% to $3.2 billion in 2023, then grew by 2.29% to $3.3 billion in 2024.